Coartem® (Artemether-Lumefantrine) for Infants and Young Children: A Critical Advance in Pediatric Malaria Treatment
Malaria remains a leading cause of illness and death among children under five in sub-Saharan Africa, where the burden of disease is highest. For newborns and young infants, effective treatment options have historically been limited, leaving this vulnerable population at significant risk. Recent regulatory advancements have addressed this critical gap with the approval of a specialized formulation of artemether-lumefantrine designed specifically for infants and very young children.
Artemether-lumefantrine, marketed under the brand name Coartem® among others, is a fixed-dose combination antimalarial medication recommended by the World Health Organization for the treatment of uncomplicated Plasmodium falciparum malaria. It combines two active ingredients: artemether, a rapidly acting artemisinin derivative, and lumefantrine, a longer-acting partner drug. This combination works synergistically to kill malaria parasites in the bloodstream and prevent recrudescence.
For many years, the standard Coartem® tablet formulation was not suitable for infants weighing less than 5 kg due to challenges in dosing and administration. Recognizing this unmet medical require, Novartis developed a dispersible, low-dose version of artemether-lumefantrine tailored for babies and young children weighing between 3 kg and less than 15 kg. This pediatric formulation contains 20 mg of artemether and 120 mg of lumefantrine per tablet, which is one-fifth the strength of the standard adult tablet.
The infant-specific Coartem® tablets are designed to disperse quickly in small amounts of liquid, including breast milk, making them easier to administer to young children who cannot swallow whole tablets. The formulation as well features a cherry flavor to improve palatability and caregiver adherence to the full three-day treatment course.
In July 2025, Swissmedic, the Swiss Agency for Therapeutic Products, granted approval for this lower-dose, dispersible artemether-lumefantrine formulation as the first malaria treatment specifically designed for infants and very young children. This approval marked a significant milestone in pediatric malaria care, particularly for neonates and infants under 6 months of age, who were previously excluded from effective artemisinin-based combination therapy due to lack of appropriate dosing options.
Following Swissmedic’s decision, the medication is anticipated to receive rapid regulatory review and approval in eight African countries participating in a coordinated assessment process. These nations, which bear a disproportionate share of the global malaria burden, are preparing to introduce the infant formulation into national treatment guidelines to expand access to effective care for their youngest patients.
Clinical use of the infant Coartem® formulation follows the same dosing schedule as the standard version: administered orally twice daily for three days, with each dose taken with food or breast milk to enhance absorption. If a child vomits within one to two hours of taking a dose, caregivers are advised to repeat the full dose. If vomiting occurs again after the repeat dose, medical consultation is required.
As with all antimalarial treatments, artemether-lumefantrine is not indicated for the prevention of malaria. It is also not recommended for severe malaria cases requiring parenteral therapy. intravenous artesunate remains the first-line treatment for severe malaria in both children and adults according to CDC and WHO guidelines.
Common side effects associated with artemether-lumefantrine include headache, fever, loss of appetite, muscle pain, and joint pain. While generally well-tolerated, the medication can prolong the QT interval in rare cases, necessitating caution in patients with known cardiac conditions or those taking other QT-prolonging drugs. However, current evidence supports its safety profile in pediatric populations, including infants, when used as directed.
The introduction of an age-appropriate, palatable, and easily administered formulation of artemether-lumefantrine represents a critical step toward reducing malaria-related mortality in infants and young children. By closing a long-standing treatment gap, this innovation has the potential to improve survival rates and health outcomes for the most vulnerable populations in malaria-endemic regions. Continued efforts to ensure widespread access, proper training for healthcare workers, and caregiver education will be essential to maximizing the public health impact of this advancement.